Article Abstract

Solithromycin: the future of macrolide is now

Authors: Rosario Menéndez, Raul Méndez


The pipeline of new antibiotics in community-acquired infection has been scarce in the last decades. Community-acquired pneumonia (CAP) remains as one of the main causes of mortality in the world and is responsible for many exacerbations of several comorbid conditions (1). Among the modifiable factors with a positive impact on CAP survival are those dependent on physician decisions, such as severity assessment and adequateness of prompt antibiotic treatment.